Repros Therapeutics announced it will complete enrollment in its Proellex-V, or vaginally delivered Proellex Phase 2 study in the treatment of uterine fibroids at the end of this month. The company believes it will be able to report study results near year end with the goal to move to Phase 3 early next year.
Apple came under fire Tuesday at a Senate hearing over an investigation that alleged the tech icon has kept billions …